Research-Grade Retatrutide | CAS 2381089-83-2 LY3437943 10mg Vials Fast Delivery
TDS 7467 Inquiries
2381089-83-2
Pharmaceutical Grade
99%
GZ
DX
15mg/vial,10vials/box
Yes
2026-08-31
GLP-1,trizepatide,Semaglutide,Retatrutide
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceRetatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.Certificates-
TDS
Basic Info-
Product Name:
Retatrutide
Other Name:Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide
CAS No.:2381089-83-2
InChIKeys:MLOLQJNKXBNWFW-SAGGEDDASA-N
Molecular Weight:0
EC Number:200-001-8
Color/Form:White lyophilized
Categories:
Characteristics-
Water Solubility:
Soluble in water (5mg/ml).
Storage Conditions:-20°C
Critical Temperature & Pressure:-20°C
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
GLP-1,trizepatide,Semaglutide,Retatrutide
-
Location:
Room 2012, No. 6-143, Section 2, Shanghai Road, Guta District, Jinzhou City, Liaoning Province
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
2 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2024
-
-
Inquiry History7467 Inquiries
Country Product Purchase Quantity Date Posted
Canada
Retatrutide
1 G Oct 26, 2026
Switzerland
Retatrutide
1 KG Oct 26, 2026
United States
Retatrutide
10 MG Oct 26, 2026
Australia
Retatrutide
30 MG Oct 26, 2026
United States
Retatrutide
30 MG Oct 26, 2026
United States
Tesa
2 MG Oct 25, 2026
Colombia
Retatrutide
15 MG Oct 25, 2026
United States
Retatrutide
10 G Oct 25, 2026
Canada
Retatrutide
1 KG Oct 25, 2026
United Kingdom
Retatrutide
1 G Oct 25, 2026
Netherlands
Retatrutide
10 MG Oct 25, 2026
Australia
Retatrutide
10 MG Oct 25, 2026
Netherlands
Retatrutide
20 MG Oct 25, 2026
Germany
Retatrutide
1 KG Oct 25, 2026
United Kingdom
Retatrutide
10 G Oct 25, 2026
United States
Retatrutide
20 MG Oct 25, 2026
Poland
Retatrutide
20 MG Oct 25, 2026
United States
Retatrutide
10 MT Oct 25, 2026
United States
Retatrutide
300 MG Oct 25, 2026
Germany
Retatrutide
1 MT Oct 24, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Hot selling high purity synergistic weight management peptide cagrilintide
Pharmaceutical Grade / 99%
-
-
-
-
High purity 99% HMG wholesale fast delivery factory derect supply cas no 61489-71-2
Pharmaceutical Grade / 99.9%
-
-
-
-
Factory derect supply high purity over 99% snap-8 lyophilized powder package 10mg/vial
Pharmaceutical Grade / 99%
-
-
-
-
Sermorlin Acetate 2mg 5mg 10mg Lyophilized Powder Vials 99% High Purity Peptide
Pharmaceutical Grade / 99.9%
-
-
-
-
Over 99% Purity Pharmaceutical Grade 5-amino-1mq white powder cas 42464-96-0 Raw material powder
Pharmaceutical Grade / 99.9%
-
-
-
-
High purity over 99% Minoxidil fast delivery cas no 38304-91-5 raw material
Pharmaceutical Grade / 99%
-
